Catalog No.
DHH02206
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Concentration
3.3 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q15116
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BGB-A317, CAS: 1858168-59-8
Clone ID
Tislelizumab
Tislelizumab: First Approval, PMID: 32185681
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC), PMID: 33044117
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma, PMID: 32561664
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study, PMID: 31520078
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study, PMID: 32561638
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors, PMID: 32540858
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma, PMID: 33047430
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma, PMID: 30969136
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial, PMID: 31378459
A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients, PMID: 32769013
Tislelizumab for the treatment of classical Hodgkin's lymphoma, PMID: 33332484
Antibodies to watch in 2019, PMID: 30516432
Nivolumab for the treatment of hepatocellular carcinoma, PMID: 30304963
Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma, PMID: 33043992
Immuno-oncology for esophageal cancer, PMID: 32777942
Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study, PMID: 32690666
Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy, PMID: 32446372
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances, PMID: 30380773
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies, PMID: 31362369
Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage, PMID: 33527708
Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab-related colitis, PMID: 32239681
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial, PMID: 33792623
Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer, PMID: 31808542
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial, PMID: 34033975
Tislelizumab-A Promising New Option for Enhancing Chemotherapy Benefit in Treatment for Advanced Squamous Cell Lung Cancer, PMID: 33792622
Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report, PMID: 34459463
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma, PMID: 34269067
Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma, PMID: 33868256
Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide, PMID: 34322131
Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer, PMID: 33866751
Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection, PMID: 33869071
Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report, PMID: 34368325
Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report, PMID: 33656285
Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response, PMID: 33334744
Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient, PMID: 34040602
Successful treatment of two patients with unresectable lung squamous cell carcinoma with tislelizumab regardless of programmed death-ligand 1 expression: a report of two cases, PMID: 34459453
A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research, PMID: 31475974
Landscape of immune checkpoint inhibitor-related adverse events in Chinese population, PMID: 32968172
Outcome of autoimmune cytopenia after hematopoietic cell transplantation in primary immunodeficiency, PMID: 32442647
Association of Hypoactive and Hyperactive Delirium With Cognitive Function After Critical Illness, PMID: 32317589
Corrigendum to "A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients" [Lung Cancer 147 (2020) 259-268], PMID: 34127281
Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond, PMID: 33602008
Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma, PMID: 33224963
Successful treatment of metastatic colorectal cancer with synchronous BRAF V600E mutation and dMMR with BGB-A317, PMID: 32172642
Successful Outcome of Programmed Death 1 Blockade Plus GemOx for Epstein-Barr Virus-Associated Primary Nodal T/NK Cell Lymphoma: A Case Report, PMID: 34277451
Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD, PMID: 33868266
Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma, PMID: 33732355
Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives, PMID: 34305619
Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer, PMID: 34095230
Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature, PMID: 34044548
For research use only. Not for human or drug use.
